Sana Biotechnology, Inc. is a US-based pharmaceutical company with a medium ESG risk rating score of 26.8. Specializing in biotechnology, Sana Biotechnology develops engineered cells to treat various diseases such as oncology, diabetes, autoimmune, and CNS disorders. With a pipeline of product candidates including SC291, SC262, SC255, and UP421, the company aims to address unmet treatment needs across different therapeutic areas.